150 related articles for article (PubMed ID: 37996105)
1. Cystic fibrosis: What next for the "wonder drug" Kaftrio?
Wise J
BMJ; 2023 Nov; 383():2766. PubMed ID: 37996105
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
3. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
De la Hoz D; Villamil Osorio M; Restrepo-Gualteros SM
Arch Argent Pediatr; 2019 Apr; 117(2):e131-e136. PubMed ID: 30869491
[TBL] [Abstract][Full Text] [Related]
5. A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.
Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E
J Clin Pharm Ther; 2021 Apr; 46(2):286-294. PubMed ID: 33285018
[TBL] [Abstract][Full Text] [Related]
6. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
7. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.
Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M
BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030
[TBL] [Abstract][Full Text] [Related]
8. Drug bests cystic-fibrosis mutation.
Ledford H
Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
[No Abstract] [Full Text] [Related]
9. Ivacaftor for patients with cystic fibrosis.
Wainwright CE
Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
[TBL] [Abstract][Full Text] [Related]
10. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
[TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.
Jiménez-Gómez M; Díaz Campos RM; Diab Cáceres L
Arch Bronconeumol; 2023 Aug; 59(8):512-513. PubMed ID: 37127448
[No Abstract] [Full Text] [Related]
12. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators.
Noy E; Senderowitz H
ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046
[No Abstract] [Full Text] [Related]
13. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
[TBL] [Abstract][Full Text] [Related]
14. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
15. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
16. How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?
Pilewski JM; Frizzell RA
Curr Opin Pulm Med; 1995 Nov; 1(6):435-43. PubMed ID: 9363079
[TBL] [Abstract][Full Text] [Related]
17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacologic therapies for cystic fibrosis.
Zeitlin PL
J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
[No Abstract] [Full Text] [Related]
19. [Modifier genes and cystic fibrosis].
Corvol H; Flamant C; Vallet C; Clement A; Brouard J
Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
[TBL] [Abstract][Full Text] [Related]
20. Quest for cystic fibrosis pharmacotherapy.
Joo NS
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):861-2. PubMed ID: 18714439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
